Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Cytomegalovirus (CMV)
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Livtencity
LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
Fabry Disease
Type 2 Diabetes Mellitus
Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Disease
Hypertension